Ambrose Cell Therapy is advancing an Adipose-Derived Regenerative Cell (ADRC) platform through an FDA pivotal study, with the lead indication targeting Ehlers-Danlos Syndrome (EDS) — a connective-tissue disorder estimated to affect millions worldwide and with no approved disease-modifying therapy.
The company's ACT4EDS trial is led by Dr. Clair Francomano, a leading EDS clinician with 40+ years in the field, alongside Dr. Cindy Farach-Carson at UTHealth and a regulatory team that has shepherded multiple cell-therapy programs through FDA Investigational New Drug pathways. The combination of a defined patient population, a seasoned trial team, and a platform technology with multi-indication optionality is what attracted Ramsey to the position.
Ramsey's involvement is consistent with the firm's three-decade pattern of backing medical technologies through commercialization with a long-hold posture rather than a venture flip. Detailed materials are available to qualified investors and counterparties on request.
Ramsey's track record is built one position at a time — entered with conviction, held through development, and exited with discipline. The fuller story for each realization will live on this page in a future phase. To discuss what we learned and how it informs current allocation, request an introduction.